Everything tagged "medical devices" across the TickerSpark archives.
Insulet is delivering strong Omnipod growth, expanding margins, and rising EPS, but management is already signaling slower growth ahead. The stock looks attractive for long-term investors, though valuation leaves less room for error.
Medline is growing quickly on Prime Vendor wins and Medline Brand conversion, but leverage, margin pressure, and a rich valuation keep the stock at Hold. The report sees durable long-term fundamentals, with fair value set at $45.00.
ResMed combines durable sleep-apnea demand, connected digital health, and expanding margins. The report supports a Buy view despite valuation discipline and product-transition risks.
Stryker posted 7.7% organic sales growth and 10.3% adjusted EPS growth in Q3, with Mako and broad segment momentum supporting a Buy rating despite a rich valuation.
Boston Scientific is a high-quality medtech franchise with strong cash generation and a broad pipeline, but near-term growth is being pressured by EP, WATCHMAN, and China-related weakness. The stock looks attractive for patient investors, with multiple recovery catalysts still ahead.
Glaukos is scaling rapidly on iDose TR and Epioxa, with Q3 revenue up 58% and 2027 sales guidance topping $1.0B. The stock still screens as a Hold because premium valuation and ongoing losses leave limited margin for error.
GE HealthCare Technologies Inc. (GEHC) rises after a broad Q3 beat that went beyond the headline. This deep-dive covers margin expansion, segment strength, cash flow gains, and the company’s raised full-year outlook, showing how volume, pricing, and execution drove the move.
GE HealthCare Technologies Inc. (GEHC) rises after reporting earnings beats, lifting shares 8.0% as investors react to stronger-than-expected results and improved outlook.
GE HealthCare is gaining traction from strong imaging and pharmaceutical diagnostics growth, but Patient Care Solutions remains a drag. The stock looks fairly valued with a Hold rating and a $76 fair value estimate.
DexCom posted 13% Q2 revenue growth, 46% EPS growth, and raised 2026 guidance, but the stock still screens as a Hold at a rich valuation. The report highlights expanding reimbursement, strong G7 15 Day adoption, and a growing opportunity in non-insulin type 2 diabetes.
Abbott Laboratories earns a Buy as medical devices and FreeStyle Libre power growth, while margin improvement and raised guidance support the case. Valuation is still premium, so the stock looks attractive but not cheap.
H.B. Fuller is showing improving margins, solid cash generation, and a credible medical adhesives growth story. Leverage and acquisition integration risk keep the stock in Hold territory despite attractive valuation.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime